Cargando…
Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity
Doxorubicin (DOX) is a well-known chemotherapeutic agent extensively applied in the field of cancer therapy. However, similar to other chemotherapeutic agents such as cisplatin, paclitaxel, docetaxel, etoposide and oxaliplatin, cancer cells are able to obtain chemoresistance that limits DOX efficacy...
Autores principales: | Ashrafizadeh, Milad, Zarrabi, Ali, Hashemi, Farid, Zabolian, Amirhossein, Saleki, Hossein, Bagherian, Morteza, Azami, Negar, Bejandi, Atefe Kazemzade, Hushmandi, Kiavash, Ang, Hui Li, Makvandi, Pooyan, Khan, Haroon, Kumar, Alan Prem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697177/ https://www.ncbi.nlm.nih.gov/pubmed/33187385 http://dx.doi.org/10.3390/pharmaceutics12111084 |
Ejemplares similares
-
PTEN, a Barrier for Proliferation and Metastasis of Gastric Cancer Cells: From Molecular Pathways to Targeting and Regulation
por: Ashrafizadeh, Milad, et al.
Publicado: (2020) -
Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery
por: Mirzaei, Sepideh, et al.
Publicado: (2021) -
Resveratrol Modulates Transforming Growth Factor-Beta (TGF-β) Signaling Pathway for Disease Therapy: A New Insight into Its Pharmacological Activities
por: Ashrafizadeh, Milad, et al.
Publicado: (2020) -
STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
por: Ashrafizadeh, Milad, et al.
Publicado: (2020) -
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers
por: Abadi, Asal Jalal, et al.
Publicado: (2021)